



## Premature termination of a Clinical Trial

### Full title of the clinical Trial:

*Phase II Study of Neratinib and Trastuzumab +/- Vinorelbine p.o. in Pre-treated Metastatic HER2-positive Breast Cancer (Ner-Her-1)*

### EudraCT Number:

*2022-002582-15*

**Sponsor:** Medical University of Graz

### Represented by (name):

Univ.-Prof. PD Dr. Marija Balic

### Reason for premature termination of the clinical trial:

*The PI left the centre before the start of the study. No patients were enrolled.*

### Study results (if available):

*Not applicable.*

### Date and Signature of Sponsor representative:

13.01.2025